What is the recommended treatment schedule for oligometastatic prostate cancer?

Treatment Schedule for Oligometastatic Prostate Cancer

For oligometastatic castration-sensitive prostate cancer (mCSPC), metastasis-directed therapy (MDT) should be offered to patients with ≤5 metastases (bone or lymph nodes), combined with ADT plus an androgen receptor pathway inhibitor (ARPI) such as abiraterone, apalutamide, darolutamide, or enzalutamide. 1

Defining Oligometastatic Disease

The definition of oligometastatic prostate cancer depends on imaging modality:

• ≤5 metastases on conventional imaging (CT, MRI, bone scan) 1
• ≤10 metastases on PSMA-PET imaging (though ≤5 remains the most validated threshold) 1
• Metastases must be limited to bone and/or lymph nodes only (no visceral disease for most MDT approaches) 1

Treatment Algorithm by Clinical Scenario

Metachronous Oligometastatic Disease (Recurrence After Prior Local Therapy)

This has the strongest evidence base:

Primary Approach:

• MDT with stereotactic body radiotherapy (SBRT) to all visible metastatic sites 1
• Radiation doses: Conventional 54 Gy or hypofractionated stereotactic regimens (median 24 Gy, range 20-27 Gy) 2
• Combine with short-course ADT (duration 6-12 months based on emerging data) 1
• Consider adding ARPI (abiraterone, enzalutamide, apalutamide, or darolutamide) for 6-12 months 1

Evidence: The STOMP trial demonstrated improved ADT-free survival (21 vs 13 months; HR 0.60) with MDT versus observation in patients with ≤3 metastases 3. The ORIOLE trial showed significantly reduced risk of progression (HR 0.30) with SBRT versus observation 1.

Synchronous Oligometastatic Disease (De Novo Metastases at Diagnosis)

For Low-Volume Disease (≤3 bone metastases, none outside spine/pelvis, no visceral):

Triplet Therapy:

• ADT + ARPI + EBRT to primary tumor 1
• Abiraterone 1,000 mg daily with prednisone 5 mg daily (continuous until progression) 4
• OR Enzalutamide 160 mg daily 4
• OR Apalutamide 240 mg daily 4
• OR Darolutamide 600 mg twice daily 1
• EBRT to prostate: Standard fractionation or hypofractionated regimens 1

Add MDT to Metastatic Sites:

• SBRT to all oligometastatic lesions (≤5 sites) 1
• This is based on PEACE-1 trial data showing improved radiographic PFS (4.4 vs 7.5 years) when RT to primary was added to abiraterone in low-volume disease 1

Alternative for Chemotherapy-Fit Patients:

• ADT + Docetaxel (6 cycles at 75 mg/m² every 3 weeks) + ARPI 1
• Add EBRT to primary tumor 1
• Consider MDT to oligometastatic sites 1

For High-Volume Disease (≥4 bone metastases with ≥1 outside spine/pelvis, OR visceral metastases):

MDT is not recommended as standard. Focus on systemic therapy:

• ADT + ARPI (doublet) 1, 4
• OR ADT + Docetaxel + ARPI (triplet) for fit patients 1
• EBRT to primary may still reduce genitourinary toxicity but oncologic benefit less clear 1

Critical Treatment Nuances

Timing and Sequencing:

• Initiate systemic therapy first (ADT ± ARPI), then add MDT within 2-3 months 1
• For metachronous disease, MDT can be delivered at time of oligometastatic detection
• All visible metastatic sites should be treated with MDT when feasible 1

Duration of Systemic Therapy:

• Continuous ADT is maintained throughout 1
• ARPI duration: Continue until progression in synchronous disease 4
• For metachronous disease with MDT: Consider 6-12 months of ADT ± ARPI based on emerging data, though optimal duration remains under investigation 1

Radiation Specifications:

• Primary tumor EBRT: Definitive doses (typically 74-80 Gy conventional or equivalent hypofractionated) 1
• MDT to metastases: SBRT with ablative doses (e.g., 24-27 Gy in 3 fractions for bone, 30-50 Gy in 3-5 fractions for nodes) 2
• Pelvic nodal RT: Consider whole pelvic RT (45-50 Gy) if regional nodes involved 1

Common Pitfalls to Avoid

1. Don't use MDT alone without systemic therapy in synchronous disease - The evidence supports combination approaches 1

2. Don't apply high-volume disease criteria to oligometastatic patients - These are distinct populations requiring different treatment intensification 4

3. Don't treat with ADT monotherapy - Combination therapy (ADT + ARPI or ADT + docetaxel) is strongly recommended unless clear contraindications exist 1

4. Don't use conventional imaging alone for oligometastatic staging - PSMA-PET significantly improves detection and may change management in 20-30% of cases 1

5. Don't forget to treat the primary tumor in low-volume synchronous disease - EBRT to prostate improves outcomes when combined with systemic therapy 1

Patient Selection Criteria

Ideal candidates for MDT:

• ECOG performance status 0-1 2
• Life expectancy >5 years 1
• ≤5 metastases on PSMA-PET (or ≤3 on conventional imaging) 1
• Bone and/or lymph node metastases only 1
• Metachronous presentation shows strongest benefit 1, 3

Relative contraindications:

• Visceral metastases (except in select clinical trials) 1
• Rapidly progressive disease (PSA doubling time <3 months) 1
• Poor performance status or limited life expectancy 1